Instem plc Director Shareholding and Other Holdings (0658K)

TIDMINS

RNS Number : 0658K

Instem plc

23 December 2015

Instem plc

("Instem" or the "Company")

Director Shareholding and Other Holdings in the Company

Instem (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, was notified today of the following deals in the ordinary shares of 10 pence each in the Company ("Ordinary Shares") by David Gare, Chairman.

David Gare is a trustee of the 'The DG 2008 Discretionary Settlement' (the "Trust") which on 23(rd) December 2015 transferred 80,000 Ordinary Shares to each of two beneficiaries, Michael Adrian Gare and Deborah Jane Walker, at a price of two hundred and thirty pence per Ordinary Share (the "Transaction").

Following the Transaction, the notifiable interests of the above parties are as follows:

 
                          Number of Ordinary   Percentage of Total 
                                 Shares Held       Ordinary Shares 
-----------------------  -------------------  -------------------- 
 David Gare, Chairman*             2,118,427                 16.2% 
-----------------------  -------------------  -------------------- 
 Michael Adrian Gare                 784,219                  6.0% 
-----------------------  -------------------  -------------------- 
 Deborah Jane Walker                 784,219                  6.0% 
-----------------------  -------------------  --------------------

*Note: these 2,118,427 Ordinary Shares are held by the Trust.

For further information, please contact:

 
 Instem plc                       +44 (0) 1785 825 600 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 N+1 Singer (Nominated Adviser 
  & Broker)                       +44 (0) 20 7496 3000 
 Richard Lindley 
 
 Walbrook Financial PR            +44 (0) 20 7933 8780 
 Paul Cornelius                   instem@walbrookpr.com 
 Helen Cresswell 
  Sam Allen

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, the United Kingdom, India and China, with additional presence in France and Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSTJBJTMBBTBIA

(END) Dow Jones Newswires

December 23, 2015 08:15 ET (13:15 GMT)

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024